Baxalta Gets EU Thumbs Up For Newly Acquired ALL Drug
This article was originally published in Scrip
Executive Summary
Baxalta Inc. has secured a nod from European regulators for the approval of its acute lymphocytic leukemia (ALL) drug, Oncaspar (pegaspargase) – a product it picked up via a $900m acquisition of Sigma-Tau Finanziaria's product portfolio earlier this year.